

The text in English is a free translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text will take precedence.

MINUTES kept at the annual general meeting with the shareholders of **Promore Pharma AB**, Reg. No. 556639-6809, on 27 June 2023 in Solna.

§ 1

Anders Björnsson opened the meeting.

It was decided, in accordance with the Nomination Committee's proposal, to elect Anders Björnsson as Chairman of the meeting. It was noted that Erik Magnusson had been assigned to keep the minutes at the meeting.

§ 2

A voting list was established and approved, Appendix 1.

§ 3

It was decided to approve the agenda proposed in the notice of the meeting.

§ 4

It was decided to elect Göran Linder and Arne Andersson to approve the minutes.

§ 5

It was decided to declare the meeting duly convened.

§ 6

It was noted that the annual report and the auditor's report and also the group accounts and the auditor's report for the group for the financial year 2022 were presented.

§ 7

The CEO, Jonas Ekblom, held a speech on the business year of 2022.

The text in English is a free translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text will take precedence.

§ 8 a

It was decided to adopt the profit and loss account and balance sheet, and also the consolidated profit and loss account and consolidated balance sheet, for the financial year 2022.

§ 8 b

It was decided, in accordance with the Board's proposal, that the available profits of SEK 11,165,107 will be transferred in new account.

§ 8 c

It was decided to discharge the directors and the CEO from liability for the management of the company in the financial year 2022.

It was noted that the CEO and the directors who own shares in the company, did not participate in this decision in respect to their own part.

§ 9

Marianne Dicander Alexandersson presented the Nomination Committee's proposal.

It was decided, in accordance with the Nomination Committee's proposal, that the Board is to consist of five directors with no alternates for the period until the end of the next annual general meeting.

It was decided, in accordance with the Nomination Committee's proposal, that the company will have one auditor with no alternate for the period until the end of the next annual general meeting.

§ 10

It was decided, in accordance with the Nomination Committee's proposal, that fees to the directors for the period until the end of the next annual general meeting will total SEK 900,000, whereof SEK 300,000 be paid to the Chairman of the Board and SEK 150,000 each to the other directors.

It was decided, in accordance with the Nomination Committee's proposal, that fees will be paid to the auditor on current account.

§ 11

It was decided, in accordance with the Nomination Committee's proposal, to re-elect Marianne Dicander Alexandersson, Hans-Peter Ostler, Göran Linder, Kerstin Valinder Strinnholm and Candice Jung as directors for the period until the end of the next annual general meeting.

It was decided, in accordance with the Nomination Committee's proposal, to re-elect Marianne Dicander Alexandersson as Chairman of the Board for the period until the end of the next annual general meeting.

The text in English is a free translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text will take precedence.

It was decided, in accordance with the Nomination Committee's proposal, to re-elect the registered audit company Finnhammars Revisionsbyrå AB as auditor for the period until the end of the next annual general meeting. It was noted that Finnhammars Revisionsbyrå AB had informed the company that Per-Olov Strand is the person appointed to have main responsibility for the audit.

§ 12

It was decided, in accordance with the Board's proposal, to authorise the Board to issue new shares, convertible instruments and warrants, Appendix 2.

It was noted that the decision was taken unanimously.

§ 13

The Chairman closed the meeting.

At the minutes:

Erik Magnusson

Approved:

Anders Björnsson

Göran Linder

Arne Andersson

The text in English is an unofficial translation of the Swedish original wording. If there are differences between the English translation and the Swedish original, the Swedish text takes precedence.

VOTING LIST

Annual general meeting in Promore Pharma AB (publ)
on 27 June 2023

Name	Number of shares and votes	Total number of shares and votes
Göran Linder <i>as a proxy for</i> Corespring New Technology AB	22,710,730	22,710,730
Erik Magnusson	82,982	82,982
Arne Andersson	3,303,874	3,303,874

Total number of shares and votes present: 26,097,586

Total number of shares and votes in the company: 60,713,936

The text in English is an unofficial translation of the Swedish original wording. If there are differences between the English translation and the Swedish original, the Swedish text takes precedence.

ITEM 12

PROPOSAL BY THE BOARD ON AUTHORIZATION

The Board of Promore Pharma AB (publ) proposes that the general meeting authorizes the Board, on one or several occasions during the period up to the next Annual General Meeting, to resolve upon an issue of new shares, convertible instruments and warrants in accordance with the following.

The Board will be authorized to resolve upon a new issue of shares, convertible instruments and warrants with or without deviation from the shareholders' preferential rights and/or with terms on payment in cash, payment-in-kind, set-off or otherwise with particular terms and conditions.

Upon disapplication from the shareholders' preferential rights, the subscription price will be determined based on the share's, convertible instrument's or warrant's market value at the time of each issue, and where applicable be subject to an issue discount at market rate.

The total number of shares to be issued, shares pursuant to convertible instrument and shares pursuant to warrants will be not more than 12,142,787 new shares, corresponding to a dilution of approximately 20 per cent.

The purpose of the proposal and the possibility of disapplication from the shareholders' preferential rights, is to increase the flexibility in acquisitions or capital raising.

The Board, or any person appointed by the Board, is authorized to make any minor adjustments to the resolution which may be required in conjunction with the registration with the Swedish Companies Office or because of other formal requirements.

A valid resolution in accordance with the Board's proposal requires that the proposal be approved by shareholders representing at least two thirds of both the votes cast as well as the shares represented at the meeting.

Solna May 2023

Promore Pharma AB (publ)

Board of Directors